AK‐2011 strain for the development of a vaccine against equine rhinopneumonitis
Rattachement africain : kz, lv. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Equine rhinopneumonitis is an acute, highly contagious disease found virtually worldwide. The purpose of the studies presented in this paper is to develop a technology for the manufacture of a cell-derived equine rhinopneumonitis vaccine, as well as to assess the safety and immunogenicity of the newly developed vaccine in laboratory animals model. The object of the studies was the AK-2011 strain isolated from the horses suffering from rhinopneumonitis during an outbreak of abortions. The viability of the AK-2011 strain was assessed using a continuous line of calf trachea cells, a continuous line of calf kidney cells, a continuous line of sheep kidney cells, a continuous line of bovine kidney cells, a continuous line of green monkey kidney cells, a continuous line of Syrian hamster kidney cells, a primary trypsinized culture of horse kidney cells grown in tubes and flasks and the AK-2011 laboratory strain of equine rhinopneumonitis virus with biological activity of 6.0 lg TCID50/cm3. Sequencing and polymerase chain reaction analysis were performed. The virus isolated from the ORF68 gene in Kazakhstan appeared to be the most similar to the T-953 and 2222-03 strains isolated in the USA and Australia, respectively, in terms of phylogenetics. As to primary infections, cytopathic effects (CPEs) induced by the AK-2011 virus stain (dilution 101) in calf trachea and horse kidney cell cultures were stable from the first to tenth passages, with biological activity of 5.75-6.00 lg TCID50/cm3. CPEs caused by the virus were apparent on days 2–3, further developed intensively and extended to 60–80% of the cell monolayer on days 5–7. The vaccine results can be used to immunize horses on farms against rhinopneumonia, and horses should be immunized twice with an interval of 2–3 months.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- AK‐2011 strain for the development of a vaccine against equine rhinopneumonitis
- Date Crossref
- 05/04/2022
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Kazakhstan Medical University pays non établi dans la noticeUniversité ou école supérieure
-
Latvia University of Life Sciences and Technologies pays non établi dans la noticeUniversité ou école supérieure
-
Laboratory of Cell Cultures and Culture Media LLP «SPE DiaVak‐ABN» Almaty Kazakhstan pays non établi dans la noticeStructure de recherche
-
Virology laboratory LLP «SPE DiaVak‐ABN» Almaty Kazakhstan pays non établi dans la noticeStructure de recherche
-
National Reference Veterinary Center Almaty Branch Almaty Kazakhstan pays non établi dans la noticeInstitution
-
Laboratory of Viral Ecology LLP «SPC of Microbiology and Virology» Almaty Kazakhstan pays non établi dans la noticeStructure de recherche
-
Faculty of Veterinary Medicine Latvia University of Agriculture Jelgava Latvia pays non établi dans la noticeUniversité ou école supérieure
-
Laboratory of Microbiology Research Institute for Biological Safety Problems Gvardeiskiy Kazakhstan pays non établi dans la noticeStructure de recherche
Kazakhstan Medical University, Latvia University of Life Sciences and Technologies et Laboratory of Cell Cultures and Culture Media LLP «SPE DiaVak‐ABN» Almaty Kazakhstan, avec 5 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.